Drug
Sibeprenlimab
Sibeprenlimab: highest development phase Phase 2, developed by Otsuka. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Otsuka
Trials
| Drug | Phase | Indication |
|---|---|---|
| Sibeprenlimab NCT06740526 | Phase 2 | IgA Nephropathy |
| Sibeprenlimab NCT06928142 | Phase 2 | Sjogren Disease |
Latest
No recent events.
Follow Sibeprenlimab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.